Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolys BioPharma's EBIT per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円-34.13.
During the past 3 years, the average EBIT per Share Growth Rate was -4.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 5.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Oncolys BioPharma's EBIT per Share or its related term are showing as below:
TSE:4588'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -65 Med: -0.7 Max: 26.8
Current: -4.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oncolys BioPharma was 26.80% per year. The lowest was -65.00% per year. And the median was -0.70% per year.
TSE:4588's 3-Year EBIT Growth Rate is ranked worse than 74.17% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs TSE:4588: -4.20
Oncolys BioPharma (TSE:4588) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Oncolys BioPharma EBIT per Share Related Terms
Oncolys BioPharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-34.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a EBIT per Share of 円-34.13 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oncolys BioPharma and its competitors. According to the industry distribution chart, Oncolys BioPharma ranks #870 out of 1173 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Oncolys BioPharma's EBIT per Share too high?
Oncolys BioPharma's current EBIT per Share is 円-34.13. Based on the distribution chart, Oncolys BioPharma ranks #870 out of 1173 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncolys BioPharma ranks #870 out of 1173 companies for EBIT per Share. This places Oncolys BioPharma in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oncolys BioPharma and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolys BioPharma's current EBIT per Share is 円-34.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円361.77, compared to a current price of 円2,351.00 — trading 549.9% above its estimated fair value. The current EBIT per Share is 円-34.13. Oncolys BioPharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current EBIT per Share is 円-34.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,351.00 is trading 549.9% above its estimated GF Value™ of 円361.77.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
EBIT per Share: 円-34.13
GF Value™: 円361.77 vs. price of 円2,351.00 (549.9% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
